Adaptive Biotechnologies Corp


Prices are adjusted according to historical splits.

Adaptive Biotechnologies Corp Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$1.28 billion
Book Value:
Revenue TTM:
$185.31 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Adaptive Biotechnologies Corp had its IPO on 2019-06-27 under the ticker symbol ADPT.

The company operates in the Healthcare sector and Biotechnology industry. Adaptive Biotechnologies Corp has a staff strength of 790 employees.

Stock update

Shares of Adaptive Biotechnologies Corp opened at $7.75 at the start of the last trading session i.e. 2023-03-25.

The stocks traded within a range of $7.67 - $8.44, and closed at $8.43.

This is a +7.53% increase from the previous day's closing price.

A total volume of 1,284,800 shares were traded at the close of the day’s session.

In the last one week, shares of Adaptive Biotechnologies Corp have increased by +0.36%.

Adaptive Biotechnologies Corp's Key Ratios

Adaptive Biotechnologies Corp has a market cap of $1.28 billion, indicating a price to book ratio of 2.4361 and a price to sales ratio of 6.6383.

In the last 12-months Adaptive Biotechnologies Corp’s revenue was $185.31 million with a gross profit of $-13657000 and an EBITDA of $-177666000. The EBITDA ratio measures Adaptive Biotechnologies Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Adaptive Biotechnologies Corp’s operating margin was -107.17% while its return on assets stood at -13.95% with a return of equity of -37.52%.

In Q4, Adaptive Biotechnologies Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 45.5%.

Adaptive Biotechnologies Corp’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Adaptive Biotechnologies Corp’s profitability.

Adaptive Biotechnologies Corp stock is trading at a EV to sales ratio of 4.6977 and a EV to EBITDA ratio of -3.9062. Its price to sales ratio in the trailing 12-months stood at 6.6383.

Adaptive Biotechnologies Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$856.62 million
Total Liabilities
$109.79 million
Operating Cash Flow
Capital Expenditure
$2.54 million
Dividend Payout Ratio

Adaptive Biotechnologies Corp ended 2023 with $856.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $856.62 million while shareholder equity stood at $464.17 million.

Adaptive Biotechnologies Corp ended 2023 with $0 in deferred long-term liabilities, $109.79 million in other current liabilities, 14000.00 in common stock, $-919082000.00 in retained earnings and $118.97 million in goodwill. Its cash balance stood at $90.03 million and cash and short-term investments were $498.20 million. The company’s total short-term debt was $9,230,000 while long-term debt stood at $0.

Adaptive Biotechnologies Corp’s total current assets stands at $562.15 million while long-term investments were $0.00 and short-term investments were $408.17 million. Its net receivables were $40.06 million compared to accounts payable of $8.08 million and inventory worth $14.45 million.

In 2023, Adaptive Biotechnologies Corp's operating cash flow was $-97544000.00 while its capital expenditure stood at $2.54 million.

Comparatively, Adaptive Biotechnologies Corp paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Adaptive Biotechnologies Corp stock is currently trading at $8.43 per share. It touched a 52-week high of $15.19 and a 52-week low of $15.19. Analysts tracking the stock have a 12-month average target price of $12.29.

Its 50-day moving average was $8.89 and 200-day moving average was $8.6 The short ratio stood at 4.09 indicating a short percent outstanding of 0%.

Around 167.3% of the company’s stock are held by insiders while 9044.1% are held by institutions.

Frequently Asked Questions About Adaptive Biotechnologies Corp

The stock symbol (also called stock or share ticker) of Adaptive Biotechnologies Corp is ADPT

The IPO of Adaptive Biotechnologies Corp took place on 2019-06-27

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.


1165 Eastlake Avenue East, Seattle, WA, United States, 98109